Rgenix Gains $40 Million in Series C Funding
Rgenix, Inc., a clinical stage biopharmaceutical company developing small molecule and antibody cancer therapeutics, raised $40 million in a Series C financing round led by Lepu Medical, a publicly traded global healthcare firm, Oceanpine Capital, and WuXi AppTec’s Corporate Venture Fund. Existing investors Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, LLC, and the Partnership Fund for New York City’s Innovate NY Fund also participated in the round.
The company plans to use the financing to support Phase 1b/2 clinical trials of the lead program RGX-104 in multiple cancer indications, including in checkpoint inhibitor refractory patients. Financing will also be used to support early clinical development of Rgenix’s cancer metabolism program RGX-202, its target discovery platform’s discovery stage programs, clinical and preclinical oncology programs, and general corporate purposes.
